STOCK TITAN

GH Research: BVF Partners may beneficially own ~12.6%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

For GH Research PLC (GHRS), three investment funds reported beneficial ownership of ordinary shares with shared voting and dispositive power. As of September 30, 2026, Biotechnology Value Fund, L.P. reported 4,507,690 shares (approximately 6.6%); Biotechnology Value Fund II, L.P. reported 3,531,790 shares (approximately 5.1%); and Biotechnology Value Trading Fund OS LP reported 610,678 shares (less than 1%).

BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., each may be deemed to beneficially own an aggregate 8,650,158 shares (approximately 12.6%); each disclaims beneficial ownership of the funds’ shares. BVF GP Holdings LLC may be deemed to beneficially own 8,039,480 shares (approximately 11.7%). The percentages are based on 68,642,287 shares outstanding as of June 30, 2026.

Biotechnology Value Fund beneficial ownership 4,507,690 shares As of September 30, 2026; approximately 6.6% of the class.
Biotechnology Value Fund II beneficial ownership 3,531,790 shares As of September 30, 2026; approximately 5.1% of the class.
Biotechnology Value Trading Fund OS beneficial ownership 610,678 shares As of September 30, 2026; less than 1% of the class.
Aggregate beneficial ownership attributed to BVF Partners, BVF Inc. and Mark N. Lampert 8,650,158 shares Each may be deemed to beneficially own approximately 12.6%.
BVF GP Holdings beneficial ownership 8,039,480 shares BVF GP Holdings LLC may be deemed to beneficially own approximately 11.7%.
Shares outstanding 68,642,287 shares As of June 30, 2026; used as the basis for the reported ownership percentages.
Shared Voting Power regulatory
"Shared Voting Power 4,507,690.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 4,507,690.00"
beneficial ownership regulatory
"may be deemed to beneficially own the 8,650,158 Shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GHRS shares did BVF's funds report owning?

As of September 30, 2026, Biotechnology Value Fund, L.P. reported 4,507,690 shares, Biotechnology Value Fund II, L.P. reported 3,531,790 shares, and Biotechnology Value Trading Fund OS LP reported 610,678 shares.

Which GHRS affiliates reported approximately 12.6% ownership?

BVF Partners L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., each may be deemed to beneficially own 8,650,158 shares, approximately 12.6%. Each disclaims beneficial ownership of the shares owned by the three funds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





G3855L106

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading